# 医疗推进剂市场 > 医疗推进剂市场研究报告信息按类型（HFA 134A、HFA 227EA、HFA152A）、按应用（定量吸入器、呼吸驱动定量吸入器）、按最终用户（医疗设备公司、合同制造组织（CMO）和研究实验室）以及按地区（北美、欧洲、亚太地区和其他地区）–市场预测至2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.16% - **2024:** $ 0.3 Billion - **2025:** $ 0.33 Billion - **2035:** $ 0.87 Billion - **Key Players:** AptarGroup (US), Honeywell International (US), 3M (US), Linde plc (GB), Air Products and Chemicals (US), Propelair (GB), Kraton Corporation (US), BASF SE (DE), Solvay SA (BE) **Report ID:** MRFR/MED/26934-CR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/medical-propellants-market-28627 --- ## Market Summary ## ** Medical Propellants Market Overview** The Medical Propellants Market was valued at USD 0.27 billion in 2023. The industry is projected to grow from USD 0.30 billion in 2024 to USD 0.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.16% during the forecast period (2024 - 2032). The rising incidence of respiratory conditions such as asthma and chronic obstructive pulmonary disease and technological advancements in inhalation devices are fueling the growth of the global metered-dose inhaler market. Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review **Medical Propellants Market****Trends** Rising incidence of respiratory conditions such as asthma and chronic obstructive pulmonary disease The increased prevalence of respiratory disorders, such as asthma and chronic obstructive pulmonary disease (COPD), is expected to have a substantial impact on the medical propellants market. This effect is mostly caused by a rise in demand for inhalation-based treatments and devices that use propellants. As respiratory illnesses become more common, increasing the demand for inhalers, which are essential devices for delivering medication to the lungs. These inhalers use propellants to deliver medication properly. For instance, the World Health Organization (WHO) claimed in 2021 that asthma impacted over 262 million people worldwide, while COPD caused roughly 3.23 million deaths in 2019. Therefore, higher prevalence rates of these diseases would increase the use of metered-dose inhalers (MDIs) and other respiratory devices, driving up demand for medical-grade propellants. The transition from chlorofluorocarbons (CFCs) to HFAs, prompted by regulatory changes and consumer demand for environmentally acceptable solutions, is stimulating innovation and growth in the medical propellants market. This growth is consistent with the growing demand for innovative inhalation medicines. Furthermore, regulations such as the Montreal Protocol have pushed companies to adopt more environmentally friendly practices. The increased regulatory focus on minimizing propellants' environmental impact is projected to promote advanced propellant market growth. Compliance with these rules and the development of innovative, environmentally friendly propellants will be critical for market players. This regulatory framework encourages growth in the sector as businesses innovate to meet new benchmarks. Hence, the increased incidence of respiratory disorders, combined with developments in inhaler technology and regulatory restrictions, is driving the medical propellants market. The rise in respiratory disease prevalence raises demand for inhalation-based treatments, broadening the market for medical propellants. As of 2024, the convergence of these elements indicates a positive picture for market expansion and technological advancement in the industry. **Medical Propellants Market****Segment Insights** **Global Medical Propellants Type Insight** Based on type, the Medical Propellants Market has been segmented into HFA 134A, HFA 227EA, and HFA-152A. The HFA 134a segment held the largest market in 2023 and the HFA-152a segment is the fastest growing segment during the forecast period, 2024–2032. The rise in respiratory diseases such as asthma and COPD globally increases the demand for inhalers, driving the market for HFA 134a propellants used in these devices. Moreover, HFA 134a is considered environmentally friendly compared to traditional chlorofluorocarbons (CFCs), making it preferred choice in medical applications following global regulatory shifts. A greater focus is also being placed on lessening the environmental effect of inhalers, which has prompted the creation and use of environmentally friendly propellants such hydrofluoroalkanes (HFAs). For instance, in March 2022, Koura (US) opened the world’s first HFA 152a medicinal propellant production facility allowing pharmaceutical companies to fulfil the 2025–2026 commercial product deadlines. Pressurized Metered Dosage Inhalers (pMDIs) will use low global warming potential (GWP) propellants, which will be produced in the new HFA 152a production facility. With the new propellant, pMDI inhalers' carbon footprint can be lowered by up to 90%, to the same degree as a dry powder inhaler (DPI). **FIGURE 2: MEDICAL PROPELLANTS MARKET SIZE, BY TYPE, 2023 & 2032 (USD BILLION)** Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review **Global Medical Propellants Application Insight** Based on application, the Medical Propellants Market has been segmented into manual metered dose inhalers and breath metered dose inhalers. The press metered dose inhalers segment held the largest market share in 2023, and the breath actuated metered dose inhalers segment is the fastest-growing segment during the forecast period (2024 -2032). The Press Metered Dose Inhalers are experiencing robust growth due to several key drivers. The increased incidence of respiratory conditions including asthma and Chronic Obstructive Pulmonary Disease (COPD), which is driving up demand for effective and convenient medication delivery methods. Furthermore, the aging population is a major factor driving the market's expansion because they are more prone to long-term respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). **Global Medical Propellants End User Insight** Based on end user, the Medical Propellants Market has been segmented into medical device companies, contract manufacturing organization (CMO) and research laboratories. The medical device companies segment held the largest market in 2023, and the contract manufacturing organization (CMO) segment is the fastest growing segment during the forecast period. Medical Device companies are growing due to rising healthcare spendings by government, private sector, and individuals. Also, the development of new hospitals, clinics, and diagnostic centers is driving the demand for a wide range of medical devices. **Global Medical Propellants Regional Insights** Based on region, the Medical Propellants Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023. However, Europe is projected to grow at the highest CAGR during the forecast period, 2024-2032 The Medical Propellants market in North America is characterized by robust growth driven by technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge Medical Propellants drives the market. Furthermore, growing adoption of telehealth may drive the demands of home-use inhalers and portable devices, increasing propellant usage and increasing elderly population present avenues for growth. Moreover, strategic partnership and collaborations are fuelling the demand for Medical Propellants in North America. The Americas region is followed by Europe, which is further segmented into the Germany, France, UK, Italy, Spain, and Rest of the Europe. The Medical Propellants market in Europe is marked by continuous innovation in propellant formulations. A mature pharmaceutical sector in Europe ensures strong distribution channel and collaborations and compliance with stringent European regulations ensures high safety and efficacy standards, instilling confidence among consumers. The increasing prevalence of respiratory diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality Inhalers. For instance, according to European Commission, On January 1, 2023, the EU population was anticipated to be 448.8 million individuals, with more than one-fifth (21.3%) of those aged 65 years or older. Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors. Rapid growing healthcare infrastructure and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated for inhalers using medical propellants. The rising prevalence of respiratory diseases, and an aging population further drive the need for innovative solutions.  **FIGURE 3: MEDICAL PROPELLANTS MARKET BY REGION 2023 & 2032 (USD BILLION)** **Global Medical Propellants Key Market Players & Competitive Insights** The Medical Propellants Market is distinguished by the presence of numerous global, regional and local players catering to the Medical Propellants Market. Furthermore, the rising incidence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) and technological advancements in inhalation devices are driving the growth of the Medical Propellants Market during the forecast period. The Medical Propellants Market is extremely competitive, with players competing and investing heavily in the development of innovative products to gain a significant market share. The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that increasing investment by the biopharmaceutical industry associated with Medical Propellants will also boost the market's growth in the upcoming future. Koura Global is a leading entity in the fluorochemical industry, renowned for its innovation and commitment to sustainability. The company specializes in the development and production of high-performance fluorochemicals, including refrigerants, solvents, and specialty chemicals. In March 2022, Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies, has opened a new HFA 152a production facility at their Runcorn site in the United Kingdom. Chiesi, an international pharmaceuticals and healthcare group focused on research, has signed a commercial agreement to use the new low-carbon footprint medical propellant for inhalation product development and clinical trials in 2019. **Key Companies in the Medical Propellants Market include** **Global Medical Propellants Industry Developments** **March 2022:**Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies, has opened a new HFA 152a production facility at their Runcorn site in the United Kingdom. Chiesi, an international pharmaceuticals and healthcare group focused on research, has signed a commercial agreement to use the new low-carbon footprint medical propellant for inhalation product development and clinical trials in 2019. **Medical Propellants Market Segmentation** **Global Medical Propellants Type Outlook** **Global Medical Propellants****Application Outlook** **Global Medical Propellants****End User Outlook** **Global Medical Propellants Regional****Outlook** ## Market Drivers ### 制药配方的进展 制药配方的创新正在显著影响医疗推进剂市场。开发需要特定推进剂特性的新的药物配方变得越来越普遍。例如，氢氟烷烃（HFA）推进剂的引入彻底改变了吸入给药系统，提供了更好的疗效和安全性。HFA推进剂的市场预计将扩展，估计年增长率约为5%。这一趋势表明，向更有效和以患者为中心的给药系统的转变，可能会增强整体市场格局。随着制药公司继续投资于研发，医疗推进剂市场有望进一步发展。 ### 吸入疗法需求上升 呼吸系统疾病（如哮喘和慢性阻塞性肺病（COPD））的日益普遍推动了对吸入疗法的需求，这些疗法利用医疗推进剂。医疗推进剂市场正在见证吸入器和雾化器的发展激增，这些设备对于有效递送药物至关重要。根据最新数据，吸入疗法细分市场预计在未来几年将以约7%的复合年增长率（CAGR）增长。这一增长主要归因于对呼吸健康的日益关注以及对有效治疗选择的需求。因此，制造商正专注于创新配方和递送机制，进一步推动医疗推进剂市场的发展。 ### 新兴市场与扩展医疗基础设施 新兴市场正在见证医疗基础设施的快速增长，这促进了医用推进剂市场的扩展。随着各国对医疗设施和服务的投资，医疗设备的需求，包括吸入产品，正在上升。这一趋势在呼吸系统疾病流行的地区尤为明显，导致对有效治疗方案的需求增加。预计在这些地区，市场将以约6%的速度增长，主要受益于医疗服务的改善和可支配收入的增加。因此，医用推进剂市场可能会经历显著的增长机会，因为制造商寻求利用这些新兴市场。 ### 对创新产品的监管支持不断增加 监管机构越来越支持创新医疗产品的发展，这对医疗推进剂市场产生了积极影响。最近旨在加快新吸入设备和推进剂审批流程的举措，鼓励制造商投资于研发。这种监管支持至关重要，因为它不仅促进了新产品更快进入市场，还确保它们符合安全和有效性标准。医疗推进剂市场可能会从这些变化中受益，因为公司有动力进行创新，推出满足患者需求的先进解决方案。预计监管批准的增长可能会导致市场环境更加动态。 ### 日益关注以患者为中心的解决方案 医疗推进剂市场正日益向以患者为中心的解决方案转变，这一转变源于对改善用户体验和遵循治疗方案的需求。制造商现在优先开发更易于使用和更方便患者的吸入设备。这一趋势在定量吸入器（MDI）和干粉吸入器（DPI）的设计中得到了体现，这些设备正被量身定制以满足不同患者群体的特定需求。对用户友好设备的重视预计将增强患者的依从性，从而增加医疗推进剂的整体需求。因此，医疗推进剂市场可能会看到销售和市场渗透率的上升。 ## Future Outlook 医疗推进剂市场预计将在2024年至2035年间以10.16%的复合年增长率增长，推动因素包括技术进步、日益增长的医疗需求和监管支持。 **New opportunities:** - 开发环保推进剂替代品 到2035年，医疗推进剂市场预计将实现强劲增长和创新。 ## Segment Insights ### 按类型：HFA 134A（最大）与 HFA 227EA（增长最快） 医疗推进剂市场展现出多样的细分价值，其中HFA 134A因其在吸入器和哮喘治疗中的广泛应用而占据市场份额的领先地位。该细分市场受益于成熟的制造工艺和监管批准，支持其在众多疗法中的采用。相反，HFA 227EA作为一个快速增长的细分市场引起了关注，主要是由于其环境优势和对医疗保健可持续性日益关注的推动。对气候变化的日益关注促使制造商转向更环保的推进剂，使HFA 227EA获得了发展动力。 增长趋势表明HFA 134A和HFA 227EA均具有强大的潜力，HFA 134A在短期内可能仍将保持主导地位。然而，监管框架和消费者偏好的持续发展正有利于HFA 227EA，使其在未来几年内具备显著的市场增长潜力。尽管HFA 152A被视为一个新兴选项，但预计在生产规模和市场准备方面将面临挑战，影响其在这一特定细分市场的竞争地位。 HFA 134A（主导）与 HFA 152A（新兴） HFA 134A 被认为是医疗推进剂市场的主导推进剂，因其高效性和在定量吸入器中的既定作用而受到青睐。它与各种配方的兼容性使其成为制造商的首选。相比之下，HFA 152A 是一个新兴领域，由于其低环境影响而展现出有前景的替代方案。然而，HFA 152A 仍在获得认可的过程中，需要进一步发展以匹配 HFA 134A 的既定市场地位。随着监管政策越来越倾向于更环保的替代品，HFA 152A 具有增长潜力，尽管目前在市场上的可用性和认知度有限。 ### 按应用：压缩计量吸入器（最大）与呼吸驱动计量吸入器（增长最快） 在医疗推进剂市场中，按压计量吸入器（pMDIs）已确立了主导地位，对整体市场份额贡献显著。该细分市场在治疗呼吸系统疾病（如哮喘和慢性阻塞性肺病）方面的广泛接受度解释了其显著存在。呼吸驱动计量吸入器（baMDIs）虽然目前市场规模较小，但由于其用户友好的设计和可及性，尤其受到儿科和老年人群体的青睐，正在获得关注。 应用：pMDIs（主导）与baMDIs（新兴） 按压式定量吸入器是医疗推进剂市场的主导投递方式，以其可靠性和有效的剂量投递而受到赞赏。它们在慢性呼吸治疗中的广泛使用巩固了它们在医疗提供者中的地位。另一方面，呼吸激活式定量吸入器代表了一种新兴趋势，强调通过吸入激活的使用便利性，从而增强患者的依从性。这些设备因其能够减少不当使用的潜力而越来越受欢迎，成为不同能力患者的有利选择。该领域的创新表明，吸入治疗正朝着更直观的方向发展。 ### 按最终用户：医疗器械公司（最大）与合同制造组织（CMO）（增长最快） 医疗推进剂市场呈现出多样化的格局，其主要终端用户为医疗器械公司、合同制造组织（CMOs）和研究实验室。医疗器械公司目前主导着市场细分，因为它们对推进剂在吸入器和气雾剂输送系统等各种应用中的需求非常大。相比之下，CMOs 正在占据越来越大的市场份额，这得益于将制造服务外包给能够提供具有成本效益和高效解决方案的专业实体的趋势日益上升。研究实验室也发挥着关键作用，尽管市场份额较小，主要用于实验和研究目的的医疗推进剂。 医疗推进剂市场的增长趋势受到技术进步和对创新医疗解决方案日益重视的显著影响。预计医疗器械公司将继续保持其主导地位，因为产品开发不断进行，并且向更复杂的输送机制转变。CMOs 预计将实现最快的增长，得益于其适应市场需求变化和提升生产流程的能力。对医疗研究的日益关注也推动研究实验室扩大对医疗推进剂的使用，以支持各种实验需求。 医疗器械公司（主导）与研究实验室（新兴） 医疗器械公司在医疗推进剂市场中占据主导地位，以其在开发和分销依赖推进剂系统的各种医疗产品方面的关键作用而闻名。这些公司处于创新吸入疗法和先进气雾剂应用的前沿。它们与医疗服务提供者和监管机构建立的良好关系进一步巩固了其市场地位。相对而言，研究实验室代表了新兴领域，越来越多地利用医疗推进剂进行实验和开发。尽管它们的市场份额相对较小，但对健康研究和开发的投资不断增加正在促进其扩展。研究实验室在适应新技术和方法方面的灵活性也使其在推进剂应用的未来中成为关键参与者。 ## Regional Market Share Analysis ### 北美：创新的市场领导者 北美是医疗推进剂最大的市场，约占全球市场份额的45%。该地区受益于先进的医疗基础设施、对吸入疗法日益增长的需求以及促进安全性和有效性的严格监管标准。像AptarGroup和霍尼韦尔国际这样的关键企业的存在进一步推动了市场增长，支持着推进剂配方的持续创新。 美国是该地区的领先国家，具有强大的竞争格局，显著的研发投资。加拿大也发挥着重要作用，凭借其不断增长的医疗保健部门为市场做出贡献。主要公司如3M和空气产品与化学品公司等塑造了竞争动态，这些公司不断提升其产品以满足监管要求和消费者需求。 ### 欧洲：监管框架推动增长 欧洲是医疗推进剂第二大市场，约占全球市场份额的30%。该地区的增长受到医疗支出增加、老年人口上升以及确保产品安全性和有效性的严格法规的推动。欧洲药品管理局（EMA）在塑造监管环境方面发挥着关键作用，促进创新，同时确保遵守健康标准。 德国、法国和英国是欧洲的主要国家，像巴斯夫和索尔维这样的关键企业的存在增强了市场竞争力。竞争格局的特点是公司之间的合作与伙伴关系，以开发先进的推进剂技术。对可持续和环保推进剂的关注也在增加，与该地区的环境目标相一致。 ### 亚太地区：快速增长与扩张 亚太地区的医疗推进剂市场正在快速增长，约占全球市场份额的20%。该地区的扩张受到医疗保健可及性增加、可支配收入上升以及呼吸系统疾病日益普遍的推动。中国和印度等国处于前沿，得益于政府旨在改善医疗基础设施和获取基本药物的倡议。 中国是该地区最大的市场，受到对医疗和制药行业的重大投资的推动。印度紧随其后，吸入疗法市场蓬勃发展。竞争格局中既有本地企业也有国际企业，包括克拉通公司和林德公司，他们积极创新以满足多样化的人口需求并遵守不断变化的法规。 ### 中东和非洲：医疗保健的未开发潜力 中东和非洲（MEA）地区正在成为医疗推进剂的潜在市场，目前约占全球市场份额的5%。增长受到医疗投资增加、对呼吸系统疾病认识提高以及政府旨在改善医疗保健可及性的倡议的推动。南非和阿联酋等国走在前列，在医疗基础设施和制药开发方面进行了重大投资。 南非是该地区最大的市场，受到对吸入疗法需求增长的支持。阿联酋也在取得进展，专注于提升医疗服务。竞争格局的特点是本地和国际企业的存在，包括Propelair和空气产品与化学品公司，他们正在探索扩大市场份额的机会，以满足对医疗推进剂日益增长的需求。 ## Competitive Benchmarking 医疗推进剂市场的特点是众多全球、区域和地方参与者为医疗推进剂市场提供服务。此外，呼吸系统疾病（如哮喘和慢性阻塞性肺病（COPD））的发病率上升以及吸入设备的技术进步正在推动医疗推进剂市场在预测期内的增长。 医疗推进剂市场竞争非常激烈，参与者在创新产品的开发上投入重金，以获得显著的市场份额。 主要行业参与者的增长依赖于多种因素，如市场条件、产品差异化和创新以及定价策略。预计与医疗推进剂市场相关的生物制药行业的投资增加也将推动市场在未来的增长。 Koura Global是氟化学行业的领先实体，以其创新和对可持续发展的承诺而闻名。该公司专注于高性能氟化学品的开发和生产，包括制冷剂、溶剂和特种化学品。 2022年3月，Koura，一家全球领先的氟产品和技术的开发、制造和供应商，在其位于英国伦敦的Runcorn工厂开设了一座新的HFA 152a生产设施。Chiesi，一家专注于研究的国际制药和医疗保健集团，于2019年签署了一项商业协议，以使用新的低碳足迹医疗推进剂进行吸入产品开发和临床试验。 ## Recent News & Developments **2022年3月：**Koura是一家全球领先的氟产品和技术的开发、制造和供应商，已在其位于英国的伦康工厂开设了一座新的HFA 152a生产设施。Chiesi是一家专注于研究的国际制药和医疗保健集团，已于2019年签署了一项商业协议，以使用这种新的低碳足迹医疗推进剂进行吸入产品的开发和临床试验。 ## Report Scope | 2024年市场规模 | 0.3（十亿美元） | | --- | --- | | 2025年市场规模 | 0.3305（十亿美元） | | 2035年市场规模 | 0.8699（十亿美元） | | 复合年增长率（CAGR） | 10.16%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 环保推进剂的进步推动了医疗推进剂市场的创新。 | | 主要市场动态 | 对环保医疗推进剂的需求上升推动了医疗行业的创新和合规。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，医疗推进剂市场的预计市场估值是多少？** A: 医疗推进剂市场预计到2035年将达到约8.699亿美元。 **Q: 2024年医疗推进剂市场的市场估值是多少？** A: 2024年，医疗推进剂市场的价值为3亿美元。 **Q: 在2025年至2035年的预测期内，医疗推进剂市场的预期CAGR是多少？** A: 预计2025年至2035年期间，医疗推进剂市场的年均增长率（CAGR）为10.16%。 **Q: 在医疗推进剂市场中，哪些公司被视为关键参与者？** A: 医疗推进剂市场的主要参与者包括AptarGroup、霍尼韦尔国际、3M、林德公司和空气产品与化学品公司。 **Q: 目前市场上主要的医疗推进剂类型有哪些？** A: 主要的医疗推进剂类型包括HFA 134A、HFA 227EA和HFA-152A，估值范围从0.1到0.3199亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/medical-propellants-market-28627*